Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete or Partial Responders
Latest Information Update: 07 Jun 2025
At a glance
- Drugs Obinutuzumab (Primary)
- Indications CNS cancer; Lymphoma
- Focus Therapeutic Use
Most Recent Events
- 07 Feb 2025 Planned number of patients changed from 30 to 28.
- 18 Mar 2024 Status changed from not yet recruiting to recruiting.
- 21 Dec 2023 New trial record